- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 24-02-2026: Press Release
24-02-2026 | 09:04 pm
24-02-2026 | 09:04 pm
Biocon secures US FDA approval for its weight management drug, Liraglutide (gSaxenda®). This strategic milestone targets the US GLP-1 market, which recorded a $127 million (~1054 Cr) opportunity for weight loss therapies (IQVIA MAT Dec 2025), positioning Biocon for significant growth.
No comments yet. Be the first to comment!